// October 14, 2025
Concentrated origins, widespread risk: New USP insights on key starting materials...
Understanding where pharmaceutical KSMs are made can help address vulnerabilities in the medicine supply chain.
Supply Chain
// October 11, 2023
Standards on the Frontlines: Responding to public health crises and strengthening sup...
Vulnerabilities or disruptions to the global medicine supply chain (including drug shortages) continue to make headlines.
// October 13, 2021
Standards Enable a Strong Medicines Supply Chain
Standards Enable a Strong Medicines Supply Chain
Standards play an important role in the global medicines supply chain, helping governments and manufacturers increase the availability of safe, quality medicines, as well as building patient and health provider trust. In fact, quality standards are a big reason why we in the U.S. can get a prescription filled at our neighborhood pharmacy and trust that the medicine we receive will be safe and work as it should.
// February 19, 2025
India and the United States manufacture most finished medicines for the U.S. market...
Natural disasters, trade wars and pandemics are just some of the disruptions that the U.S. pharmaceutical supply chain has faced in recent years. Identifying where drug products are made is a first step in characterizing the risk associated with these events. Learn more.
// November 06, 2024
Global manufacturing capacity for active pharmaceutical ingredients remains concentra...
The globalization of the medicines supply chain has helped to increase access to quality medicines at a lower cost. At the same time, the supply chain has grown longer, more complex, and fragmented, leading to a lack of visibility and increase in the risk to its resilience. In many instances, globalization has also led to the concentration of production in a few geographies. Insights from USP’s Medicine Supply Map demonstrate that geographic concentration of pharmaceutical manufacturing anywhere in the world – including within the United States – increases the risk for drug shortages.
// September 10, 2024
Korea’s Minister of Food & Drug Safety: Addressing Medicines Supply Chain Resilience ...
Building on the momentum of recent high-level engagements with health agencies from around the world, USP hosted a delegation from the Republic of Korea’s (South Korea) National Institute of Food and Drug Safety Evaluation (NIFDS) at our U.S. hub in Rockville, MD.
// September 09, 2024
Why Standards Matter in Digital Therapeutics
Maryland, MD—United States Pharmacopeia (USP) Healthcare Quality and Safety (HQS) Center of Excellence is examining the current landscape of Digital Therapeutics (DTx) to establish quality standards aimed at broadening access and ensuring appropriate use of these therapeutics.
Show 11 More